---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-013802"
form_type: "8-K"
ticker: "HRMY"
cik: "0001802665"
company_name: "Harmony Biosciences Holdings, Inc."
filed_at: "2024-10-29T23:59:59+00:00"
generated_at: "2026-05-30T09:21:57.289567+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Harmony Biosciences Q3 net revenue $186M (+16% YoY); reiterates FY2024 guidance $700-720M

## Summary
- GAAP net income $46.1M ($0.79 diluted EPS) vs $38.5M ($0.63) in Q3 2023; non-GAAP adjusted EPS $1.03.
- Average WAKIX patients ~6,800 (+250 sequentially); cumulative net revenue surpasses $2B since 2019 launch.
- On track to submit sNDA for pitolisant in idiopathic hypersomnia in Q4 2024; LTS data show sustained efficacy.
- Pipeline: EPX-100 Phase 3 for Dravet syndrome (data 2026); Phase 3 for LGS to start by year-end; ZYN-002 topline mid-2025.
- Reiterates FY2024 net product revenue guidance of $700-$720 million.

## SEC filing metadata
- accession: 0001558370-24-013802
- form_type: 8-K
- ticker: HRMY
- cik: 0001802665
- company_name: Harmony Biosciences Holdings, Inc.
- filed_at: 2024-10-29T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1802665/000155837024013802/0001558370-24-013802-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1802665/000155837024013802/hrmy-20241029x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-013802
- JSON: https://secwatch.observer/filing/0001558370-24-013802.json
- Plain text: https://secwatch.observer/filing/0001558370-24-013802.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.